| Literature DB >> 32851774 |
Geeta Rao1, Shailendra Kumar Dhar Dwivedi2, Yushan Zhang1, Anindya Dey2, Khader Shameer3, Ramachandran Karthik4, Subramanya Srikantan4, Md Nazir Hossen1, Jonathan D Wren5, Muniswamy Madesh4, Joel T Dudley3, Resham Bhattacharya2,6, Priyabrata Mukherjee1,6.
Abstract
MICU1 is a mitochondrial inner membrane protein that inhibits mitochondrial calcium entry; elevated MICU1 expression is characteristic of many cancers, including ovarian cancer. MICU1 induces both glycolysis and chemoresistance and is associated with poor clinical outcomes. However, there are currently no available interventions to normalize aberrant MICU1 expression. Here, we demonstrate that microRNA-195-5p (miR-195) directly targets the 3' UTR of the MICU1 mRNA and represses MICU1 expression. Additionally, miR-195 is under-expressed in ovarian cancer cell lines, and restoring miR-195 expression reestablishes native MICU1 levels and the associated phenotypes. Stable expression of miR-195 in a human xenograft model of ovarian cancer significantly reduces tumor growth, increases tumor doubling times, and enhances overall survival. In conclusion, miR-195 controls MICU1 levels in ovarian cancer and could be exploited to normalize aberrant MICU1 expression, thus reversing both glycolysis and chemoresistance and consequently improving patient outcomes.Entities:
Keywords: MICU1/CBARA1; Ovarian cancer; chemoresistance; glycolysis; miR-195
Mesh:
Substances:
Year: 2020 PMID: 32851774 PMCID: PMC7534609 DOI: 10.15252/embr.201948483
Source DB: PubMed Journal: EMBO Rep ISSN: 1469-221X Impact factor: 9.071